Daniel C. Parker, MD, presented “Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP): Rationale, Selection & Technique” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.
How to cite: Parker, Daniel C. “Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP): Rationale, Selection & Technique” September 13th, 2019. Accessed Nov 2024. https://grandroundsinurology.com/new-approaches-to-metastatic-hormone-sensitive-prostate-cancer/
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP): Rationale, Selection & Technique – Summary:
Daniel C. Parker, MD, an assistant professor of urology at the University of Oklahoma, discusses the functional outcomes of the Retzius-sparing robotic-assisted laparoscopic prostatectomy (RARP) as compared to a traditional RARP. He goes on to describe the differences in postoperative continence and erectile disruption between the two approaches, how to select patients who may be candidates for a Retzius-sparing approach, as well as several randomized studies that describe any oncological and functional outcome differences between the two approaches.
About The 5th Annual Prostate & Urologic Cancer Symposium:
The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Parker presented this lecture during the 5th iteration of this summit in 2019.
ABOUT THE AUTHOR
Daniel C. Parker, MD, is a urologic oncologist at the Stephenson Cancer Center, which is based at the University of Oklahoma Health Sciences Center in Oklahoma City. He also serves as an Assistant Professor of Urology at the University of Oklahoma College of Medicine. Dr. Parker was the first graduate from the Stephenson Cancer Center’s new Urologic Oncology Fellowship Program, accredited by the Society of Urologic Oncology. The Prostate and Urologic Oncology Program at the Stephenson Cancer Center is made up of six fellowship-trained urologic oncologists, the largest group of such physicians in the state. Their team leads the state in prostate and urologic cancer therapies, offering unique services such as minimally invasive surgery, MRI-fusion guided prostate biopsies, and focal therapy for prostate cancer (HIFU). Prior to his fellowship training, Dr. Parker completed a urology and general surgery residency at Temple University Hospital in Philadelphia and served as Chief Resident in Urologic Oncology at Fox Chase Cancer Center, part of the Temple Health System in Philadelphia. He earned his medical degree at OU College of Medicine and an undergraduate degree from the University of Oklahoma.
Dr. Parker has a focus on academic medicine and clinical research, and has already authored 11 peer-reviewed publications and five book chapters. He is always looking to expand his own education and as such is currently enrolled in a competitive master’s degree program at the Harvard T.H. Chan School of Public Health, where he is focusing on health services and outcomes research.
